Stocks
Axsome Therapeutics (AXSM) EBITDA margin US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -348.2% | -83.1% | -89.4% | |||||
| Changes by years, y/y, % | +265pp | -76.1% | |||||||
Axsome Therapeutics. EBITDA margin, %
Axsome Therapeutics. EBITDA margin, changes, pp
Axsome Therapeutics (AXSM) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | -104.5% | -135.0% | -87.3% | -89.5% | -59.8% | -89.4% | |
| Changes by years, y/y, % | +136pp | +85pp | -82pp | +33pp | +45pp | |||
| Changes by quarters, q/q, % | +18pp | -30pp | +48pp | -2pp | +30pp | |||
